Trial Profile
Effects of postoperative palonosetron in ambulatory patients identified with high risk for postdischarge nausea and vomiting (PDNV) – a randomized controlled trial with comparison to placebo.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 03 Jul 2020
Price :
$35
*
At a glance
- Drugs Palonosetron (Primary)
- Indications Postoperative nausea and vomiting
- Focus Therapeutic Use
- Acronyms POSTPAL
- 03 Jul 2020 Status changed from recruiting to completed.
- 27 May 2016 New trial record